<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03987711</url>
  </required_header>
  <id_info>
    <org_study_id>SAFE-D-01</org_study_id>
    <nct_id>NCT03987711</nct_id>
  </id_info>
  <brief_title>Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis</brief_title>
  <acronym>SAFE-D</acronym>
  <official_title>Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis (SAFE-D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unity Health Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The George Institute for Global Health (Sydney, Australia)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Unity Health Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevention of atrial fibrillation related thromboembolism in the dialysis population is&#xD;
      unclear. While the practice of anticoagulation appears favorable in patients with&#xD;
      mild-to-moderate chronic kidney disease, no patients with severe chronic kidney disease&#xD;
      (estimated glomerular filtration rate &lt;25 ml/min), and specifically those receiving dialysis,&#xD;
      have been included in randomized trials.Moreover, the effect of anticoagulation in the&#xD;
      dialysis population may fundamentally differ from those studied in clinical trials.&#xD;
      Accordingly, characterization of the optimal management strategy to reduce the risk of stroke&#xD;
      and systemic embolism in patients with atrial fibrillation receiving dialysis is a priority.&#xD;
      The overall goal of this pilot trial is to evaluate the feasibility of conducting a&#xD;
      randomized controlled trial comparing anticoagulation strategies in patients with atrial&#xD;
      fibrillation receiving dialysis (either hemodialysis or peritoneal dialysis).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment of the target population within 2 years</measure>
    <time_frame>2 years from start of trial</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>At least 80% of randomized participants remain in the trial and on the allocated study treatment at the end of the 26-week study period.</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients randomized to warfarin achieving a Time in the Therapeutic Range (TTR) &gt;65%.</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&gt;95% of randomized patients adhere to the enrollment criteria with respect to atrial fibrillation or atrial flutter</measure>
    <time_frame>End of trial</time_frame>
    <description>Through adjudication of ECGs or other cardiac diagnostics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>26 weeks</time_frame>
    <description>As defined by the International Society of Thrombosis and Haemostasis (ISTH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically relevant non-major bleeding</measure>
    <time_frame>26 weeks</time_frame>
    <description>As defined by the International Society of Thrombosis and Haemostasis (ISTH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke and systemic embolism</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal myocardial infarction</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular events not related to dialysis access</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Events of special interest related to dialysis access, the dialysis procedure or the oral anticoagulants</measure>
    <time_frame>26 weeks</time_frame>
    <description>Thrombosis of fistula or graft; fistula or graft abandonment; thrombosis of dialysis catheter; red blood cell transfusions; calciphylaxis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>End Stage Renal Failure on Dialysis</condition>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals randomized to this arm will be exposed to dose-adjusted daily warfarin targeting an international normalized ratio (INR) of 2.0-3.0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apixaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individuals randomized to this arm will receive apixaban 5 mg twice daily (a reduced dose of 2.5 mg twice daily will be given to selected participants).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No oral anticoagulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individuals in this arm will be exposed to a treatment strategy in which no oral anticoagulation is prescribed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Individuals randomized to this arm will be exposed to dose-adjusted daily warfarin targeting an international normalized ratio (INR) of 2.0-3.0.</description>
    <arm_group_label>Warfarin</arm_group_label>
    <other_name>Coumadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Individuals randomized to this arm will receive apixaban 5 mg twice daily (a reduced dose of 2.5 mg twice daily will be given to selected participants).</description>
    <arm_group_label>Apixaban</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No oral anticoagulation</intervention_name>
    <description>No oral anticoagulation</description>
    <arm_group_label>No oral anticoagulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years.&#xD;
&#xD;
          2. Receiving maintenance hemodialysis or peritoneal dialysis for &gt; 90 days.&#xD;
&#xD;
          3. History of AF or atrial flutter as defined by:&#xD;
&#xD;
             (i) AF or atrial flutter on a 12 lead ECG at enrollment, and not due to a reversible&#xD;
             cause, or (ii) AF or atrial flutter documented on two separate occasions, not due to a&#xD;
             reversible cause, at least 1 day apart prior to enrollment. AF or atrial flutter may&#xD;
             be documented by ECG, or as an episode lasting at least 30 seconds on a rhythm strip&#xD;
             or Holter recording, or more than 30 minutes if using pacemaker or implantable&#xD;
             cardioverter defibrillator (ICD) recordings, or (iii) AF or atrial flutter documented&#xD;
             on one occasion, not due to a reversible cause, prior to enrollment and being treated&#xD;
             with an oral anticoagulant for AF or atrial flutter at enrollment. [AF or atrial&#xD;
             flutter may be documented by ECG, or as an episode lasting at least 30 seconds on a&#xD;
             rhythm strip or Holter recording, or more than 30 minutes if using pacemaker or&#xD;
             implantable cardioverter defibrillator (ICD) recordings, or mentioned in the medical&#xD;
             record], or (iv) AF or atrial flutter documented on one occasion on ECG, not due to a&#xD;
             reversible cause, prior to enrollment and at least one more episode of AF or atrial&#xD;
             flutter mentioned in the medical record, or (v) AF or atrial flutter documented on one&#xD;
             occasion in a cardiologist report, not due to a reversible condition, prior to&#xD;
             enrollment.&#xD;
&#xD;
          4. Satisfying CHADS-65 criteria: i) Age ≥65 or ii) Age &lt;65 and one of: hypertension,&#xD;
             diabetes mellitus, congestive heart failure, stroke/transient ischemic attack or&#xD;
             peripheral embolism.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Moderate or severe mitral stenosis.&#xD;
&#xD;
          2. Conditions other than non-valvular atrial fibrillation that require oral&#xD;
             anticoagulation, such as mechanical prosthetic valve, deep venous thrombosis, or&#xD;
             pulmonary embolism.&#xD;
&#xD;
          3. Need for aspirin at a dose &gt; 165 mg a day, or need for aspirin in combination with&#xD;
             P2Y12 antagonist therapy.&#xD;
&#xD;
          4. Need for an interacting drug which precludes the safe use of apixaban.&#xD;
&#xD;
          5. Life expectancy &lt; 6 months.&#xD;
&#xD;
          6. Scheduled live-donor kidney transplant in the next 6 months.&#xD;
&#xD;
          7. A woman who is pregnant or breastfeeding or unwilling to pursue methods of&#xD;
             contraception if &lt; 12 months since the last menstrual period.&#xD;
&#xD;
          8. Co-enrollment in a clinical trial where the intervention is deemed to interfere with&#xD;
             the adherence, safety or efficacy of the intervention provided herein.&#xD;
&#xD;
          9. Patient's attending physician(s) (e.g., nephrologist and/or cardiologist and/or&#xD;
             neurologist) believes that oral anticoagulation is absolutely mandated.&#xD;
&#xD;
         10. Patient's attending physician(s) (e.g., nephrologist and/or cardiologist and/or&#xD;
             neurologist) believes that oral anticoagulation is absolutely contraindicated.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ziv Harel</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unity Health Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ron Wald</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unity Health Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ziv Harel</last_name>
    <phone>416-360-4000</phone>
    <phone_ext>8462</phone_ext>
    <email>ziv.harel@unityhealth.to</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ron Wald</last_name>
    <phone>416-867-3703</phone>
    <email>ron.wald@unityhealth.to</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. George Hospital</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brendan Smyth</last_name>
      <phone>+61 2 8052 4658</phone>
      <email>bsmyth@georgeinstitute.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Sunil Badve</last_name>
      <phone>+61 2 8052 4636</phone>
      <email>sbadve@georgeinstitute.org.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Seven Oaks General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2V 3M3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Rigatto</last_name>
      <email>crigatto@sbgh.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Claudio Rigatto</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clara Bohm</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Health Authority, QEII Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karthik Tennankore</last_name>
      <phone>902-473-2099</phone>
      <email>karthikk.tennankore@nshealth.ca</email>
    </contact>
    <investigator>
      <last_name>Karthik Tennankore</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Clark</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Soroka</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amanda Vinson</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Walsh</last_name>
      <phone>905-522-1155</phone>
      <email>lastwalsh1975@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Michael Walsh</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Rabbat</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Lanktree</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lonnie Pyne</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre - Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Silver</last_name>
      <email>samuel.silver@queensu.ca</email>
    </contact>
    <investigator>
      <last_name>Samuel Silver</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eduard Iliescu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Weir</last_name>
      <phone>519-663-2998</phone>
      <email>matthew.weir@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Matthew Weir</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lakshman Gunaratnam</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health Oshawa</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Steele</last_name>
      <phone>905-576-8711 x33200</phone>
      <email>asteele@lh.ca</email>
    </contact>
    <investigator>
      <last_name>Andrew Steele</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nancy Barrese</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Buldo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Wei</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital - Riverside Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Clark</last_name>
    </contact>
    <investigator>
      <last_name>Edward Clark</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deborah Zimmerman</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Sciences North</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Paul Harmon</last_name>
      <email>jharmon@hsnsudbury.ca</email>
    </contact>
    <investigator>
      <last_name>John Paul Harmon</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Goluch</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Sciences Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rey Acedillo</last_name>
      <phone>807-684-7566</phone>
      <email>acedillr@tbh.net</email>
    </contact>
    <investigator>
      <last_name>Rey Acedillo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nasim Shahbazi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Oliver, M.D.</last_name>
      <phone>416-480-4755</phone>
      <email>matthew.oliver@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Matthew Oliver, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sheldon Tobe, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unity Health Toronto, at its St. Michael's Hospital site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ziv Harel</last_name>
      <phone>416-360-4000</phone>
      <phone_ext>8462</phone_ext>
      <email>ziv.harel@unityhealth.to</email>
    </contact>
    <investigator>
      <last_name>Ziv Harel</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ron Wald</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Perl</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network - Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6K3S2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charmaine Lok</last_name>
      <email>charmaine.lok@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Charmaine Lok, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abhijat Kitchlu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Health Centre Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6R 1B5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Sasal</last_name>
      <phone>416-530-6227</phone>
      <email>joanna.sasal@unityhealth.to</email>
    </contact>
    <investigator>
      <last_name>Joanna Sasal</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ron Wald</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H8S 4K4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Suri</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>35203</phone_ext>
      <email>Rita.suri@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Rita Suri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Maisonneuve-Rosemont</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georges Ouellet</last_name>
      <phone>514-252-3400</phone>
      <phone_ext>3654</phone_ext>
      <email>gouellet.hmr@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Georges Ouellet</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Philippe Lafrance</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annie Claire Nadeau-Fredette</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent Pichette</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Beaubien-Souligny</last_name>
      <phone>514-377-3733</phone>
      <email>william.beaubien@gmail.com</email>
    </contact>
    <investigator>
      <last_name>William Beaubien-Souligny</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre Granger-Vallée</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Blum</last_name>
      <phone>514-340-8222 x24249</phone>
      <email>daniel.blum@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Daniel Blum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital du Sacré-Cœur de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Madore</last_name>
      <phone>514-338-2222</phone>
      <email>f.madore@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>François Madore</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rémi Goupil</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Québec - Université Laval</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice Mac-Way</last_name>
      <phone>418-525-4444 x15464</phone>
      <email>fabrice.mac-way@chudequebec.ca</email>
    </contact>
    <investigator>
      <last_name>Fabrice Mac-Way</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simon Desmeules</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathieu Rousseau-Gagnon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sébastien Xavier Joncas</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regina General Hospital</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4P 0W5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bhanu Prasad</last_name>
      <phone>306-352-3018</phone>
      <email>bprasad@sasktel.net</email>
    </contact>
    <investigator>
      <last_name>Bhanu Prasad</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Payam Dehghani</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 12, 2019</study_first_submitted>
  <study_first_submitted_qc>June 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2019</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

